In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).

Wierzbowski AK; Karlowsky JA; Hoban DJ

首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).

【24h】

In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).

机译：研究中的酮内酯头霉素对大环内酯类和青霉素耐药性肺炎链球菌的体外活性：1998年至2006年加拿大呼吸器官易感性研究（CROSS）的综述。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Ketolides are a family of macrolide-lincosamide-streptogramin B ('MLS_B') antimicrobials that were mainly developed to overcome macrolide resistance in pneumococci and are an attractive alternative for the treatment of respiratory tract infections in areas with significant macrolide resistance. Telithromycin's pharma-codynamic/pharmacokinetic properties suggest optimal efficacy for isolates with MICs of <0.25 mg/L. Telithromycin was the first member of this new class approved for clinical use with indications for community-acquired pneumonia (CAP).

机译：酮内酯是大环内酯-林可酰胺-链霉菌素B（'MLS_B'）抗菌剂家族，主要开发用于克服肺炎链球菌中的大环内酯耐药性，并且是在大环内酯耐药性显着地区治疗呼吸道感染的有吸引力的替代方法。 Telithromycin的药代动力学/药代动力学特性表明，MICs <0.25 mg / L的分离株具有最佳功效。 Telithromycin是该新类别的首个被批准用于临床并具有社区获得性肺炎（CAP）适应症的成员。

著录项

来源
《The Journal of Antimicrobial Chemotherapy》 |2009年第3期|共3页
作者
Wierzbowski AK; Karlowsky JA; Hoban DJ;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;药学;
关键词

相似文献

外文文献
中文文献

1. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS) [J] . Aleksandra K. Wierzbowski1* James A. Karlowsky12 Daryl J. Hoban12 and George G. Zhanel1 Journal of Antimicrobial Chemotherapy . 2009,第3期

机译：研究中的酮内酯头霉素对大环内酯类和青霉素耐药性肺炎链球菌的体外活性：1998年至2006年加拿大呼吸器官易感性研究（CROSS）综述
2. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998–2004) [J] . A. K. Wierzbowski1 K. Nichol12 N. Laing1 T. Hisanaga1 A. Nikulin3 J. A. Karlowsky12 D. J. Hoban12 and G. G. Zhanel12 Journal of Antimicrobial Chemotherapy . 2007,第4期

机译：加拿大呼吸器官易感性研究（CROSS）（1998-2004）进行的6年间分离的肺炎链球菌的大环内酯耐药机制
3. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). [J] . Wierzbowski AK, Nichol K, Laing N, The Journal of Antimicrobial Chemotherapy . 2007,第4期

机译：加拿大呼吸器官易感性研究（CROSS）（1998 2004）进行了6年的分离的肺炎链球菌中的大环内酯耐药机制。
4. In Vitro Activities of Cethromycin (ABT-773) a New Ketolide against Streptococcus pneumoniae Strains That Are Not Susceptible to Penicillin or Macrolides [O] . Edward O. Mason Jr., Linda B. Lamberth, Ellen R. Wald, 2003

机译：新霉素酮类霉素红霉素（ABT-773）的抗青霉素或大环内酯类易感性肺炎链球菌菌株的体外活性
5. In Vitro Activities of Cethromycin (ABT-773), a New Ketolide, against Streptococcus pneumoniae Strains That Are Not Susceptible to Penicillin or Macrolides [O] . Mason, Edward O., Lamberth, Linda B., Wald, Ellen R., 2003

机译：新霉素酮类霉素红霉素（ABT-773）的抗青霉素或大环内酯类易感性肺炎链球菌菌株的体外活性

In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).

摘要

著录项

相似文献

相关主题

期刊订阅